CTOs on the Move

Pharma Test-Americas

www.pharma-test.ca

 
Pharma Test-Americas is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

NxStage Medical

NxStage System One dialysis machines offer the comfort and flexibility of hemodialysis at home. Discover how our products can improve your quality of life.

Surface Ophthalmics

Surface Ophthalmics, Inc. is a pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular diseases.

Amneal

Amneal (NYSE:AMRX) is building one of the most dynamic pharmaceutical companies in our industry. Today`s healthcare environment requires new ideas. While staying true to our reputation for quality, service and value in pharmaceuticals, we are challenging ourselves, our playbook and the status quo. We are uniting people, passion and products to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow`s health challenges. We are Amneal and “We make healthy possible.” Learn more about how we`re making a difference in generics, brands and biosimilars at Amneal.com.

Illyria Consulting Group

Illyria Consulting Group is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.